Nick Joseph

Joel said FDA impact is more on public markets than private, but it affects confidence in fundraising. Jenna added that FDA has tried to announce expedited review processes but it hasn't translated to private-side behavior changes yet.

Marc disclosed the wind-down reserve grew from ~$23M to $25-30M across private/public biotech and ancillary tenants. Joel noted private companies are being more aggressively wound down or combined, a new phenomenon versus historical biotech.

Joel clarified the Investor Day message: 2-3 years for core Alexandria markets (Cambridge, Watertown, Seaport) and 4-5 years for tertiary markets (Somerville, Alewife) where recovery depends on use conversion rather than lab demand.

Peter confirmed strong buyer demand especially for opportunistic assets, with no shortage of interest across life science and alternative-use properties including residential developers.

Joel clarified equity-like capital includes dividend savings and JV sales, but emphasized the vast majority of 2026 capital will come from asset dispositions.

Joel said it is hard to generalize as each submarket has unique dynamics with different headwinds and tailwinds.

Joel explained large pharma needs a world-class integrated campus rather than disaggregated buildings. Hallie added that infrastructure requirements like vibration and power capacity make build-to-suit necessary.

Joel drew parallels to GFC and dot-com bust, emphasizing doubling down on innovative companies and shaping the mega campus platform during downturns.

Marc indicated the capitalized interest adjustment is their best estimate for the year with good visibility.

Asked whether recent tech layoff announcements are affecting NorCal demand or if forward indicators remain strong.

Asked about buyer cap rates across regions with focus on a large SoCal portfolio reportedly coming to market. Probed capital allocation priorities including how buybacks compare to acquisition yields. Clarified buyer vs seller cap rate definitions.

Asked about buyer cap rates across regions with focus on a large SoCal portfolio reportedly coming to market. Probed capital allocation priorities including how buybacks compare to acquisition yields. Clarified buyer vs seller cap rate definitions.

Asked about buyer cap rates across regions with focus on a large SoCal portfolio reportedly coming to market. Probed capital allocation priorities including how buybacks compare to acquisition yields. Clarified buyer vs seller cap rate definitions.

Asked for 2026 earn-in breakdown by region and probed the sensitivity around timing of preferred equity redemptions and the 150 bps FFO headwind estimate.

Asked for 2026 earn-in breakdown by region and probed the sensitivity around timing of preferred equity redemptions and the 150 bps FFO headwind estimate.

Barb provided specific LA assumptions: occupancy improving to 96% stabilized level and rent growth modest at about 2%, with no wildfire impact factored in.

Angela explained that specific regulatory outcomes weren't baked in but the guidance range accounts for downside scenarios including eviction moratorium and rent freeze proposals.

Justin confirmed ongoing small-scale recycling of assets that don't support the growth profile. Consistent approach over past several years.

Justin stated rents need to be 20-40% higher for new supply to work. New starts likely limited to very high price point niche product disconnected from existing market.

Hutchens said pipeline very active with momentum. Half of $800M YTD was off-market. Operator relationships and repeat sellers providing differentiated access despite increased competition.

Hutchens said post-COVID infection control improvements (masks, isolation, hand hygiene) have helped. Portfolio experiencing minimal flu impacts with very few outbreak reports.

Cafaro framed portfolio as unified by longevity megatrend. Leaning heavily into senior housing to increase enterprise growth rate. Open-minded to portfolio changes to create shareholder value.

Hutchens said new capital entering but pipeline much bigger. Ventas multi-operator platform is a competitive advantage since 75% of sector is small operators with 50 or fewer assets.

Probst confirmed acquisitions are immediately accretive, part of 7% FFO/share growth, though $1B pipeline in 2025 will have lesser contribution given timing.

Hutchens detailed 7-8% year one NOI yield, low to mid-teens unlevered IRR criteria with 90% average in-place occupancy and further 10% upside.

Moses acknowledged duration still longer than peak when space was scarce. But pipeline quality much improved versus two years ago when there was more tire-kicking.

Moses said 450K of 2026 expirations fully offset by commencements. Some renewals pulled forward into 2025. Substantial majority in South San Francisco.

Brinker acknowledged most supply removed was less competitive but noted some directly competitive space exploring alternative uses. More than 4M sqft could ultimately leave lab.

Brinker said high-quality MOB cap rates are 6-7%, possibly below 6% for select assets. Life science cap rates hard to pin down except for long-term credit-tenant leases.

Bohn said pipeline is still predominantly lab users rather than office conversions.

Bohn noted larger requirements emerging across all three markets. Q4 average lease was low 40K sqft vs low 30s for first three quarters.

Mike detailed earn-in by region: East Coast 40-70 bps, West Coast 50-80 bps, Sunbelt negative 120-150 bps. Toomey added data showing cautious consumer (longer response times, traffic patterns). Strategy: occupancy first, match market on rate.

Mike confirmed spread narrowing from 450 bps in Q1 (coast +2.5%, Sunbelt -2%) to ~400 bps in Q2 (coast +4%, Sunbelt flat). Expects continued convergence in back half.

Mike explained guidance raise is driven by first-half outperformance, with revenue 80% baked through July. Acknowledged blends peaked in May and renewals will come down 100 bps in back half.

Joe expects mid-4s yield in year one on $183M basis, path to 5% over a couple years as occupancy moves from mid-85s higher.

Joe quantified minimal downside risk of 20 bps to same-store revenue if blends don't accelerate beyond mid-2s.

Management confirmed similar occupancy across JV and wholly-owned pools with structure driven by market mix rather than performance

Boyle described broad opportunities across singles/doubles, portfolios, and international, noting they underwrote ~$7B but transacted on ~$1B. Investing in data science for underwriting.

Tom explained the capital allocation framework: repurchased $200M in Q2 when stock was undervalued and acquisition volumes low; introduced ATM program for anticipated 2025 growth.

Tom confirmed 10% pricing restriction applies in LA and Ventura counties, impacting both ECRIs and new move-ins, but deflected specifics to the 100bps aggregate impact.